Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO)

Price 1.286p on 19-07-2024 at 16:30:01
Change 0.006p 0.47%
Buy 1.30p
Sell 1.272p
Buy / Sell HEMO Shares
Last Trade: Sell 100,000.00 at 1.273p
Day's Volume: 915,686
Last Close: 1.286p
Open: 1.28p
Day's Range 0.00p - 0.00p
52wk Range: 1.22p - 6.30p
Market Capitalisation: £17m
VWAP: 1.291544p
Shares in Issue: 1,342m

Recent Trades History Hemogenyx (HEMO)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 100,000 1.273p Negotiated Trade
13:21:45 - 19-Jul-24
Sell* 36,371 1.273p Negotiated Trade
12:42:19 - 19-Jul-24
Sell* 383 1.272p Ordinary
12:32:52 - 19-Jul-24
Buy* 23,727 1.30p SI Trade
11:32:40 - 19-Jul-24
Sell* 7,992 1.273p Negotiated Trade
11:25:50 - 19-Jul-24
Buy* 146,114 1.2916p Ordinary
11:24:30 - 19-Jul-24
Buy* 250,000 1.297p Suspected BUY Trade
11:08:06 - 19-Jul-24
Buy* 38,491 1.299p Suspected BUY Trade
11:05:54 - 19-Jul-24
Sell* 737 1.268p Ordinary
11:00:26 - 19-Jul-24
Buy* 45,214 1.2995p Suspected BUY Trade
10:27:22 - 19-Jul-24

Share Price History for Hemogenyx

Time period:
Date Open High Low Close Volume

Share News for Hemogenyx

UK shareholder meetings calendar - next 7 days

20th Jun 2024 15:48

Read More

IN BRIEF: Hemogenyx Pharmaceuticals updates on leukemia treatment

17th Jun 2024 19:55

Hemogenyx Pharmaceuticals PLC - biopharmaceutical company focused on treatments for blood diseases - Updates on its ongoing activities and progress. Says an additional US medical centre has been added to its list of clinical trial sites for Hemo-Car T. This will enhance the scope and expedite the timeline for the implementation of clinical trials. Hemogenyx says it is looking to expand Hemo-Car T to include pediatric acute myeloid leukemia and a subset of pediatric acute lymphoblastic leukemia patients. An amendment to the clinical protocol is currently under review by third party experts. If approved, the company will seek to implement the clinical trials for pediatric AML. Further, company says it is advancing studies for CDX, a bispecific antibody designed for treating relapsed and/or refractory AML, a subset of ALL, and for conditioning in bone marrow transplants. Read More

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

25th Apr 2024 12:19

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

29th Feb 2024 14:04

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing. Read More

Hemogenyx shares rise on potential for CBR to treat brain diseases

16th Feb 2024 11:27

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered